Sunscreen

Phase 1Small molecule

YYale University

Sunscreen is one of 20 small molecule programs targeting Skin Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin CancerNot yet recruiting

Skin CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

20 competitors in Skin Cancer

#DrugCompanyPhaseTrials

Myfortic

Novartis

Approved

1 2

Rapamune

PPrism Pharmaceuticals

Approved

2 3

Imuran

LLegacy Health System

Approved

1 4

Prograf

VVeloxis Pharmaceuticals

Approved

1 5

Farydak

Tylenol

Paraplatin

Tarceva

Peridex

DDexcel Pharma Technologies Ltd.

Phase 3

1 10

Libtayo

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Skin Cancer

NCT07286318

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Completed·—·Phase 2·NCT01867294·19 enrolled

Skin Cancer1 trial

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Not yet recruiting·MMarissa Lobl·Phase 1·NCT07286318·20 enrolled

Skin rash1 trial

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00362986·116 enrolled

Nanoparticle1 trial

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Completed·YYale University·Phase 1·NCT05736224·30 enrolled

Melasma1 trial

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

Completed·UUniversidad Autonoma de San Luis Potosí·Phase 1·NCT03392623·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sunscreen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sunscreen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sunscreen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYale University

Sunscreen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Cancer1 trial

Skin Cancer1 trial

Skin rash1 trial

Nanoparticle1 trial

Melasma1 trial

References

Drug Info

Quick Facts

Related News